The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome
Abstract
OBJECTIVE: This study addressed the unique clinical properties attributed to the atypical antipsychotic clozapine, including its efficacy in patients with treatment-refractory psychosis and against negative symptoms, its lack of acute extrapyramidal side effects, and the longer time course of its therapeutic effects. METHOD: The clinical responses of 84 schizophrenic inpatients (66 with treatment-refractory illness and 18 who were intolerant of antipsychotic treatment) were examined. After all previous antipsychotic medications had been withdrawn, the patients were treated with clozapine according to a standardized titration and dosage schedule. Patients who tolerated and responded to treatment were discharged and maintained on a regimen of clozapine for up to 52 weeks. Patients were evaluated for behavioral response and side effects after weeks 3, 6, 12, 26, 39, and 52 of treatment. RESULTS: Fifty percent of the patients with treatment-refractory illness and 76% of the treatment-intolerant patients responded to clozapine in up to 52 weeks. The optimal period for a trial of clozapine appeared to be 12-24 weeks. Clozapine exhibited therapeutic effects on negative symptoms, but these were not clearly independent of its effects on positive symptoms and extrapyramidal side effects. Several variables, including early age at onset of illness and female gender, were found to be predictors of poor response to treatment. Predictors of good response included the presence of extrapyramidal side effects during previous treatment with classic neuroleptics and a diagnosis of paranoid schizophrenia. CONCLUSIONS: These findings have important implications for the use of clozapine and our understanding of the pathophysiology of treatment-resistant schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
BMDP Statistical Software 1981.
Bubolz, T. A., & Dixon, W. J. (1984) · Journal of the American Statistical Association · doi:10.2307/2288308 · Cited by 5,221
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Duration of psychosis and outcome in first-episode schizophrenia
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.9.1183 · Cited by 880
On distribution-free tests for equality of survival distributions
TARONE, R. E., & WARE, J. (1977) · Biometrika · doi:10.1093/biomet/64.1.156 · Cited by 729
Kelly, P. H., & Iversen, S. D. (1976) · European Journal of Pharmacology · doi:10.1016/0014-2999(76)90352-6 · Cited by 715
Treatment of Negative Symptoms
Carpenter, W. T., Heinrichs, D. W., & Alphs, L. D. (1985) · Schizophrenia Bulletin · doi:10.1093/schbul/11.3.440 · Cited by 499
Pickar, D. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820050009001 · Cited by 354
Meltzer, H. Y., Burnett, S., Bastani, B., & Ramirez, L. F. (1990) · Psychiatric Services · doi:10.1176/ps.41.8.892 · Cited by 338
The Effects of Clozapine on Tardive Dyskinesia
Lieberman, J. A., Saltz, B. L., Johns, C. A., Pollack, S., Borenstein, M., & Kane, J. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.158.4.503 · Cited by 302
The Risks and Benefits of Clozapine versus Chlorpromazine
CLAGHORN, J., HONIGFELD, G., ABUZZAHAB, F. S., WANG, R., STEINBOOK, R., TUASON, V., & KLERMAN, G. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198712000-00002 · Cited by 301
The Effect of Clozapine on Cognition and Psychiatric Symptoms in Patients with Schizophrenia
Goldberg, T. E., Greenberg, R. D., Griffin, S. J., Gold, J. M., Kleinman, J. E., Pickar, D., Schulz, S. C., & Weinberger, D. R. (1993) · British Journal of Psychiatry · doi:10.1192/bjp.162.1.43 · Cited by 289
Dopaminergic Mechanisms in Idiopathic and Drug-induced Psychoses
Lieberman, J. A., Kinon, B. J., & Loebel, A. D. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.1.97 · Cited by 274
Meltzer, H. Y., Bastani, B., Kwon, K. Y., Ramirez, L. F., Burnett, S., & Sharpe, J. (1989) · Psychopharmacology · doi:10.1007/bf00442563 · Cited by 271
Dimensions of Outcome with Clozapine
Meltzer, H. Y. (1992) · British Journal of Psychiatry · doi:10.1192/s000712500029692x · Cited by 252
Clozapine: neuroleptic-induced EPS and tardive dyskinesia
Casey, D. E. (1989) · Psychopharmacology · doi:10.1007/bf00442559 · Cited by 251
Lindström, L. H. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb05164.x · Cited by 246
HLA-B38, DR4, DQw3 and Clozapine-Induced Agranulocytosis in Jewish Patients With Schizophrenia
Lieberman, J. A. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220061007 · Cited by 207
Gerlach, J., Koppelhus, P., Helweg, E., & Monrad, A. (1974) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1974.tb09706.x · Cited by 197
The Evolution of Symptoms in Institutionalized Hebephrenic/Catatonic Schizophrenics
Pfohl, B., & Winokur, G. (1982) · British Journal of Psychiatry · doi:10.1192/bjp.141.6.567 · Cited by 163
Natural History of Schizophrenia Subtypes
Fenton, W. S. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810350009002 · Cited by 151
Effects of clozapine on cerebral catecholaminergic neurone systems
Bartholini, G., Haefely, W. E., Jalfre, M., Keller, H. H., & Pletscher, A. (1972) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1972.tb06898.x · Cited by 124
Biochemical and behavioural properties of clozapine
Coward, D. M., Impérato, A., Urwyler, S., & White, T. G. (1989) · Psychopharmacology · doi:10.1007/bf00442552 · Cited by 124
Small, J. G., Milstein, V., Marhenke, J. D., et al. (1987) · PubMed · Cited by 117
Clozapine's effect on negative symptoms in treatment-refractory schizophrenics
Miller, D. D., Perry, P. J., Cadoret, R. J., & Andreasen, N. C. (1994) · Comprehensive Psychiatry · doi:10.1016/0010-440x(94)90164-3 · Cited by 110
Clozapine and the Dopamine Hypothesis of Schizophrenia, a Critical Appraisal
Bürki, H. R., Eichenberger, E., Sayers, A., & White, T. G. (1975) · Pharmacopsychiatry · doi:10.1055/s-0028-1094449 · Cited by 99
13. Early intervention with neuroleptics may decrease the l long-term morbidity of schizophrenia
Wyatt, R. J. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90073-z · Cited by 84
Ekblom, B., & Häggström, J. E. (1974) · PubMed · Cited by 70
Prevalence of tardive dyskinesia in elderly samples.
Lieberman, J. A., Kane, J. M., Woerner, M. G., Weinhold, P., Basavaraju, N. G., Kurucz, J., & Bergmann, K. J. (1984) · PubMed · Cited by 64
Response to clozapine in chronic psychotic patients.
Rr, O., Beake, B., Marby, D. W., et al. (1989) · PubMed · Cited by 52
Predictors of response to clozapine therapy
Honigfeld, G., & Patin, J. R. (1989) · Psychopharmacology · doi:10.1007/bf00442562 · Cited by 40
Halperin, R., Guerin, J. J., & Davis, K. L. (1989) · Psychopharmacology · doi:10.1007/bf00451692 · Cited by 18
Cited by
Howes, O. D., McCutcheon, R., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M. A. P., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,132
Sex differences in schizophrenia
Abel, K. M., Drake, R., & Goldstein, J. M. (2010) · International Review of Psychiatry · doi:10.3109/09540261.2010.515205 · Cited by 762
Keefe, R. S. E., Silva, S. G., Perkins, D. O., & Lieberman, J. A. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033374 · Cited by 693
A Separate Disease Within the Syndrome of Schizophrenia
Kirkpatrick, B., Buchanan, R. W., Ross, D. E., & Carpenter, W. T. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.2.165 · Cited by 651
Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 631
Metadata
- Venue
- American Journal of Psychiatry
- Published
- 1994-12-01
- Volume
- 151
- Issue
- 12
- Pages
- 1744-1752
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W940697911
- Cited by
- 382
- References
- 36
- FWCI
- 12.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.